CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28344886)

Published in Oncoimmunology on December 23, 2016

Authors

Nan Chen¹, Aurore Morello¹, Zachary Tano², Prasad S Adusumilli¹

Author Affiliations

1: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA.

Articles citing this ↘

Novel immunotherapy clinical trials in malignant pleural mesothelioma. Ann Transl Med (2017) 0.75

Articles cited by this ↗

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res (2016) 0.96